Oppenheimer Maintains Outperform on Biogen, Raises Price Target to $275

Oppenheimer analyst Jay Olson has maintained an 'Outperform' rating on Biogen (NASDAQ: BIIB) and raised the price target from $250 to $275. This adjustment reflects a positive outlook for the company in the market.